Tocilizumab subcutaneous products — Medica
Still’s disease, adult onset
Initial criteria
- age > 18 years
- prescribed by or in consultation with a rheumatologist
Reauthorization criteria
- therapy established for at least 6 months
- beneficial clinical response by objective measure OR improvement in at least one symptom
Approval duration
initial: 6 months; reauth: 1 year